Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MP0317 in advanced solid tumors
NCT05098405Phase 1Terminated
- Sponsor
- Molecular Partners AG
- Start
- Oct 2021
- Primary completion
- Jan 2024
- Modality
- Carrier/Scaffold Proteins
- Countries
- 2
01
Overview
Phase 1, open-label trial of MP0317 in solid tumor (advanced stage) (2 arms), sponsored by Molecular Partners AG. Primary endpoints: Type, incidence and severity of AEs and serious adverse events, Incidence of dose-limiting toxicities and 2 more. Started Oct 2021; status: terminated.
02
Drugs
MP0317
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT05098405.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05098405.